| Similar Articles |
|---|
 |
The Motley Fool
February 2, 2006
Brian Gorman |
Cambrex in a Crunch The drug manufacturer is suffering despite positive macro trends. For now, investors shouldn't expect much from Cambrex.   |
The Motley Fool
April 13, 2007
Brian Lawler |
Genentech Is Still Healthy The biopharma powerhouse announces its first-quarter financial results. Investors, take note. |
The Motley Fool
December 15, 2004
Brian Gorman |
Korea's Biotech Bet Korea's new facility could stimulate biotech research in Asia and lower costs for biotech companies. |
Fast Company
February 2009
Elizabeth Svoboda |
Wyeth's Multibillion-dollar Biotech Bet Drugmaker Wyeth bet billions on biotech, transforming its culture and boosting profits. |
The Motley Fool
June 22, 2005
Brian Gorman |
Biotech's Global Agenda Bristol-Myers' recent outsourcing deal illustrates the global spread of biotech investments. |
The Motley Fool
October 19, 2006
Brian Lawler |
A Yawn and More Growth From Wyeth Investors, the numbers aren't all that new, but they are good. With its guidance of $3.12 to $3.18 in EPS for the year and a steadily increasing dividend, Wyeth is a good candidate for investors who want to get a start in this sector |
The Motley Fool
December 31, 2007
Brian Lawler |
The Biotech Year in Review Following the biotech sector is never dull, and 2007 was no exception to the rule. Let's take a look at the highlights and lowlights of 2007. |
The Motley Fool
January 22, 2004
Alyce Lomax |
Worries for Wyeth Despite pain-free vaccine, the drug maker's results are still painful. |
The Motley Fool
August 29, 2008
Brian Lawler |
Will Biopharma Acquisitions Never Cease? In both the size and quantity of proposed deals, the past 24 months have been busier than ever for biopharma dealmakers. What's behind all this activity? |
The Motley Fool
February 25, 2011
Esterhuizen & Sellitti |
12 Small-Cap Biotech Stocks Being Snapped Up by Mutual Fund Investors If you're looking for small-cap biotech investing ideas, the following list might offer some good starting points. |
The Motley Fool
March 28, 2005
Brian Gorman |
A Passage to India? Changes in India's patent law could create new dynamics for the biotech and pharmaceutical industries. Investors should be on the lookout for the firms that seek to leverage these new opportunities. |
The Motley Fool
February 6, 2008
Brian Lawler |
PDL BioPharma Regroups, Piece by Piece The company still brings in plenty of money, despite selling off assets. Investors, take note. |
